Educational Notice

This article is written for researchers, clinicians, and informed consumers seeking to understand the published evidence on leuprolide. It is not medical advice, a treatment recommendation, or a substitute for professional consultation. Leuprolide is an FDA-approved prescription medication used in oncology, reproductive medicine, and gender-affirming care — all requiring physician supervision. Consult a qualified specialist before making any decisions.

A Comprehensive Evidence Review — GnRH Agonist Paradox, Prostate Cancer, Endometriosis, Gender-Affirming Care, and the Testosterone Flare

Leuprolide is one of the most commercially successful peptide drugs in history and one of the best illustrations of pharmacological paradox in all of medicine. It is a synthetic GnRH agonist — a compound that binds and activates the same receptor as the endogenous gonadotropin-releasing hormone. Yet its primary clinical applications are all built on suppression of sex hormone production: in prostate cancer, it reduces testosterone to castrate levels to starve androgen-dependent tumor growth; in endometriosis, it suppresses estrogen to induce a temporary medical menopause that reduces ectopic tissue proliferation; in central precocious puberty, it arrests premature gonadal activation; in gender-affirming care, it blocks endogenous sex hormone production to allow hormone therapy to proceed with minimal counter-hormonal interference.

How does an agonist suppress the pathway it activates? The answer is receptor desensitization and downregulation. When GnRH receptors on pituitary gonadotrophs are continuously occupied by a GnRH agonist, the cells undergo receptor internalization, uncoupling from G-protein signaling, and a refractory state where LH and FSH release ceases despite continued agonist presence. This is the pharmacological basis for all long-acting GnRH agonist drugs — leuprolide, triptorelin, and nafarelin — and it distinguishes them completely from gonadorelin, which exploits the physiological pulsatile pattern to stimulate rather than suppress.

Leuprolide’s position as a cross-cluster compound reflects the breadth of its clinical applications. It appears in this Sexual Health & Hormonal cluster because of its use in endometriosis, precocious puberty, uterine fibroids, fertility protocols, and gender-affirming care — all reproductive and hormonal medicine applications. It is simultaneously one of the most important compounds in oncology, particularly prostate cancer — where it has been standard of care for androgen deprivation therapy (ADT) for over four decades. This article covers both domains in full.

Quick Facts

Brand Names

Lupron, Lupron Depot, Eligard, Viadur (implant)

Structure

Synthetic GnRH decapeptide analog — D-Leu6, des-Gly10-NH₂ substitutions increase potency and half-life vs. native GnRH

FDA Approvals

Advanced prostate cancer; endometriosis; uterine fibroids (preoperative); central precocious puberty

Evidence Tier

Approved Drug — decades of Phase III and IV data across multiple indications

WADA Status

Not prohibited

Key Mechanism

Continuous GnRH receptor agonism → pituitary desensitization → LH/FSH suppression → castrate sex hormone levels

Testosterone Flare

Initial agonism causes transient testosterone surge before suppression — clinically significant in metastatic prostate cancer; requires flare protection with antiandrogen

Formulations

Daily SC injection (Lupron); 1-month depot IM; 3-month depot IM; 4-month depot; 6-month depot; 12-month subcutaneous implant (Viadur)

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

What Is Leuprolide?

Leuprolide acetate is a synthetic nonapeptide analog of gonadotropin-releasing hormone, developed by Takeda Pharmaceuticals and Abbott Laboratories in the late 1970s and approved by the FDA in 1985. It differs from native GnRH in two key positions: a D-leucine substitution at position 6 and removal of the C-terminal glycine amide at position 10, replaced by an N-ethylamide. These modifications increase receptor binding affinity approximately 100-fold versus native GnRH and reduce susceptibility to enzymatic degradation, extending the half-life from GnRH’s 2–4 minutes to approximately 3 hours for leuprolide. The enhanced potency and extended half-life are precisely what make leuprolide a suppressive rather than stimulatory agent: it occupies the GnRH receptor with high affinity for long enough to drive the desensitization cascade that shuts down gonadotropin secretion.

The depot formulations — where leuprolide acetate is incorporated into biodegradable polymer microspheres or gel matrices that release the drug slowly over 1, 3, 4, or 6 months — extend this principle further, providing continuous GnRH receptor occupancy for months from a single injection. The commercial success of leuprolide reflects the power of this depot principle: reliable, long-duration medical castration from a single injection, without the psychological and logistical burden of surgical orchidectomy or daily medication.

Plain English

Leuprolide is a super-powered version of the brain’s natural signal to produce sex hormones. But because it’s so powerful and lasts so long, it overwhelms the pituitary’s response mechanism — like pressing an elevator button repeatedly until the building’s system stops responding. The result is the opposite of what the signal normally does: sex hormones drop to near-zero instead of rising. This paradoxical suppression is the entire point of the drug.

Mechanism: Continuous Agonism, Paradoxical Suppression

Leuprolide binds GnRHR with approximately 100-fold greater affinity than native GnRH and occupies the receptor continuously when delivered by depot formulation. The sustained receptor occupancy initiates a desensitization cascade: GnRHR undergoes rapid internalization through clathrin-mediated endocytosis, removing receptors from the cell surface. Simultaneously, uncoupling of GnRHR from its Gq/11 transduction pathway reduces signaling even for the receptors that remain at the surface. Within 2–4 weeks of continuous agonist exposure, the net result is profound gonadotroph desensitization — LH and FSH secretion drops to near-undetectable levels despite abundant circulating GnRH agonist.

Plain English

Leuprolide works through a counterintuitive trick: it overstimulates the hormone switch so hard and so long that the switch breaks. By flooding GnRH receptors with constant signal (instead of the normal pulsing pattern), it causes the receptors to shut down within 2–4 weeks—dropping sex hormone levels to near zero. The initial burst of stimulation before shutdown is called the “flare.”

Downstream of gonadotropin suppression, the absence of LH drive to Leydig cells (in men) and theca/granulosa cells (in women) causes testosterone and estradiol production to fall to castrate levels — testosterone below 50 ng/dL in men, estradiol below 20 pg/mL in women. These are the therapeutic targets for the approved indications. Castrate testosterone starves androgen-dependent prostate cancer cells of their growth signal; castrate estradiol suppresses the estrogen-dependent proliferation of endometriosis implants and uterine fibroids; suppressed gonadotropins halt the premature HPG activation of central precocious puberty.

The Testosterone Flare: Initial Agonism Before Suppression

Before the suppressive desensitization occurs, leuprolide’s initial agonism at GnRHR produces a transient stimulatory response — a surge in LH and FSH that drives a testosterone rise in men and estradiol rise in women during the first 1–2 weeks of treatment. This “testosterone flare” can transiently increase testosterone to 1.5–2x baseline before suppression occurs. In most clinical contexts, this flare is clinically insignificant. In metastatic prostate cancer, it is potentially dangerous: a testosterone surge in a man with bone metastases can exacerbate bone pain, trigger spinal cord compression from vertebral metastases, or worsen urinary obstruction from tumor growth. This is why standard practice in metastatic prostate cancer is to co-administer a short-course antiandrogen (bicalutamide, flutamide) for the first 2–4 weeks of leuprolide therapy to block the androgen receptor during the flare period, before suppression is established.

Clinical Alert

In men with metastatic prostate cancer — particularly those with vertebral metastases, urinary obstruction, or high-volume skeletal disease — the testosterone flare from leuprolide initiation can cause clinical deterioration. Antiandrogen co-administration for the first 4 weeks of leuprolide therapy is standard practice for flare protection in this population and should not be omitted.

Prostate Cancer: Androgen Deprivation Therapy

Androgen deprivation therapy (ADT) with leuprolide is standard of care across multiple prostate cancer settings. The rationale dates to the Nobel Prize-winning observations of Charles Huggins in the 1940s that prostate cancer growth depends on androgens — castration causes disease regression in metastatic prostate cancer. Leuprolide achieves medical castration equivalent to orchidectomy, with the advantages of reversibility and avoidance of surgical morbidity.

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

ADT is the backbone of treatment for metastatic prostate cancer. Multiple Phase III trials have established that combining ADT with docetaxel (CHAARTED, STAMPEDE) or with second-generation antiandrogens (abiraterone in LATITUDE, enzalutamide in ENZAMET, apalutamide in TITAN) provides significantly longer overall survival than ADT alone. These combination regimens have transformed the metastatic hormone-sensitive landscape, with median overall survival now exceeding 4–5 years in favorable-risk patients in the best combination arms.

Biochemical Recurrence After Local Treatment

PSA rise after radical prostatectomy or radiation (biochemical recurrence) is a major clinical scenario where ADT is used, either as early intervention, combined with salvage radiation, or as longer-term disease management. Intermittent ADT — cycles of leuprolide with testosterone recovery intervals — is an established strategy that reduces cumulative side effect burden while providing similar disease control to continuous ADT in appropriately selected patients.

Castration-Resistant Prostate Cancer (CRPC)

Even when prostate cancer progresses on ADT, continued ADT to maintain castrate testosterone is standard of care. Second-line therapies (abiraterone, enzalutamide, docetaxel, cabazitaxel, PARP inhibitors for BRCA-mutated disease) are added to ongoing ADT, not used as ADT replacements.

Evidence context: Leuprolide’s prostate cancer evidence base is among the most extensive in all oncology — hundreds of Phase III trials across different disease stages, combination partners, and treatment durations. The oncology evidence is not meaningfully contested. The quality-of-life and side effect profile is the major clinical management challenge, not efficacy.

Endometriosis: Medical Menopause Induction

Endometriosis — the presence of endometrial-like tissue outside the uterus — affects approximately 10% of reproductive-age women and is a major cause of chronic pelvic pain, dysmenorrhea, dyspareunia, and infertility. Ectopic endometrial tissue is estrogen-dependent: it proliferates under estrogen stimulation and is relatively quiescent under estrogen deprivation. Leuprolide induces a temporary hypoestrogenic state equivalent to medical menopause, causing ectopic implants to regress and symptoms to improve.

FDA-approved for endometriosis with a maximum treatment duration of 6 months due to the hypoestrogenic side effects (bone loss, vasomotor symptoms). Add-back therapy with low-dose estrogen and/or progestin is commonly used to reduce hypoestrogenic side effects while preserving therapeutic benefit. After stopping leuprolide, estrogen rises and symptoms often recur — the treatment is not curative but provides meaningful symptom relief and is commonly used preoperatively to reduce lesion size before surgical excision.

Uterine Fibroids

Uterine fibroids are estrogen- and progesterone-dependent benign smooth muscle tumors of the uterus. Leuprolide is FDA-approved for the preoperative treatment of uterine fibroids — inducing fibroid shrinkage of approximately 35–60% over 3 months of treatment, reducing surgical bleeding, and improving surgical conditions. Maximum approved duration is 3 months pre-surgery, and add-back therapy is used in some protocols to limit bone loss during the course.

Central Precocious Puberty

Central precocious puberty (CPP) — gonadotropin-dependent early puberty onset before age 8 in girls or age 9 in boys — results from premature activation of the HPG axis. Leuprolide is the most widely used and best-studied treatment for CPP, suppressing the prematurely activated HPG axis and halting pubertal progression. The goals are to prevent premature bone maturation and epiphyseal fusion (which would result in short adult stature) and to allow normal psychosocial development. Treatment is continued until an age-appropriate time for puberty, at which point leuprolide is stopped and the HPG axis reactivates. Long-term follow-up data in CPP treated with leuprolide shows normal adult height attainment, normal reproductive function, and normal bone density.

Gender-Affirming Care: Puberty Suppression

Leuprolide is used off-label as a puberty suppressor in gender-dysphoric adolescents to provide time for decision-making about gender-affirming hormone therapy before irreversible secondary sex characteristics develop. The pharmacological mechanism is the same as CPP treatment — HPG axis suppression halting pubertal progression. Use in this context has become politically contentious in several countries, with legislative restrictions enacted in some states and nations. Peptidings covers the pharmacological evidence; the policy debate is outside the scope of this article.

From a pharmacological standpoint, the mechanism of leuprolide in puberty suppression for gender dysphoria is identical to its use in CPP. The differences lie in patient selection, duration of use, and the intent to subsequently use cross-sex hormones rather than resume endogenous puberty. Bone density monitoring and management (calcium, vitamin D) is important for adolescents on prolonged suppression. Published data from centers with long-term follow-up experience are accumulating.

Fertility Protocols: Controlled Ovarian Stimulation

Leuprolide is widely used in assisted reproductive technology (ART) as part of controlled ovarian stimulation (COS) protocols. In the “long protocol,” leuprolide is started in the luteal phase of the preceding cycle and used to suppress endogenous LH — preventing premature LH surge and spontaneous ovulation during the follicular stimulation phase with exogenous gonadotropins. This allows controlled, pharmacologically synchronized follicle development. Newer GnRH antagonist protocols have largely replaced the long leuprolide protocol in many centers, but the long protocol remains in use particularly in poor responders where down-regulation before stimulation is beneficial.

Key Research and Studies

The leuprolide evidence base spans four decades of controlled trials across multiple indications. Selected landmarks:

Prostate cancer: The original Phase III trials (1984–1985) established leuprolide equivalence to DES for metastatic prostate cancer with a more favorable cardiovascular safety profile, supporting initial approval. Subsequent combination trials — CHAARTED, STAMPEDE, LATITUDE, ENZAMET, TITAN — have progressively refined combination strategies and timing of ADT.

Endometriosis: Multiple randomized controlled trials over 30+ years have established leuprolide efficacy for pain relief and have defined add-back therapy principles. ACOG practice bulletins provide the evidence synthesis for clinical use.

Central precocious puberty: Long-term outcome data from large cohort studies (Carel et al., Lazar et al., and others) confirm normal adult height attainment and reproductive function after leuprolide treatment for CPP — evidence that also informs the gender-affirming puberty suppression evidence base.

Common Claims versus Current Evidence

Claim What the Evidence Shows Verdict
“Leuprolide causes immediate testosterone suppression” Testosterone first rises (flare) for 1–2 weeks, then falls to castrate levels by week 3–4. Suppression is not immediate. In sensitive patients (metastatic bone disease), flare can cause clinical harm — antiandrogen co-administration for the first 4 weeks is standard practice for this group. False — initial testosterone rise precedes suppression
“Leuprolide is chemotherapy” Leuprolide is a hormonal therapy, not cytotoxic chemotherapy. It does not kill cells directly — it removes the hormonal growth signal. The distinction matters for side effect profile, mechanism, and combination sequencing. False — hormonal therapy, not chemotherapy
“Puberty suppression with leuprolide is permanent” In CPP: long-term data confirm normal adult reproductive function after stopping. Puberty resumes after cessation. For gender-affirming use, the situation depends on whether cross-sex hormones are subsequently used — the suppression itself is reversible; downstream decisions about cross-sex hormones are a separate question. False for CPP; more complex for gender-affirming context
“Leuprolide and gonadorelin are interchangeable” Opposite effects at the HPG axis level. Leuprolide suppresses; gonadorelin (pulsatile) stimulates. They share the same receptor but produce opposite clinical outcomes through different delivery profiles. Not interchangeable for any indication. False — mechanistically related but clinically opposite

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

Safety, Risks, and Limitations

Leuprolide’s side effect profile is directly explained by testosterone (in men) and estrogen (in women) deprivation. These are on-target consequences of the drug’s mechanism — not off-target toxicities. Understanding the safety profile requires understanding that the drug is doing exactly what it is designed to do; the side effects are the cost of that intended action.

In Men (Prostate Cancer ADT)

Testosterone deprivation in men produces: hot flashes (in approximately 80% of patients), loss of libido and erectile dysfunction (nearly universal), loss of muscle mass and strength, increased fat mass (particularly visceral), osteoporosis and fracture risk (increases with ADT duration), metabolic syndrome features, anemia, fatigue, cognitive effects (memory, executive function), depression and mood changes, and gynecomastia (breast tissue development, from estrogen-to-androgen ratio change). Cardiovascular risk with long-term ADT is a major concern — the ADT cardiovascular safety literature is extensive, and the FDA label carries warnings for serious cardiovascular events, diabetes, and glucose intolerance. GnRH antagonists (degarelix) may have a more favorable cardiovascular profile than agonists (leuprolide) in patients with pre-existing cardiovascular disease, based on HERO trial data, though this comparison is still under investigation.

In Women (Endometriosis / Fibroids)

Estrogen deprivation in women produces: hot flashes (most common — affecting 75–90%), vaginal dryness and dyspareunia, decreased libido, mood changes, headaches, and bone density loss (clinically significant after 6 months, which is why the maximum approved treatment duration is 6 months without add-back therapy). Add-back therapy with low-dose norethindrone acetate and/or conjugated estrogens is established practice to manage hypoestrogenic symptoms while preserving therapeutic benefit.

In Pediatric Use (CPP)

Long-term follow-up data confirm normal adult height, bone density, and reproductive function after leuprolide treatment for CPP. Injection site reactions are the most common local adverse event in children. During treatment, bone density accrual is slower than in untreated peers — after stopping, bone density normalizes. The pediatric safety data is reassuring and extensive given decades of use for this indication.

Legal and Regulatory Status

Leuprolide (Lupron, Lupron Depot, Eligard) is FDA-approved in the United States for: advanced prostate cancer, endometriosis, uterine fibroids (preoperative only), and central precocious puberty. It is a prescription drug. Generic leuprolide acetate is available. WADA: not prohibited. In gender-affirming care, use for puberty suppression is off-label in the US but practiced under standard-of-care guidelines from WPATH, Endocrine Society, and AAP; legislative restrictions in some states affect access.

Formulations and Delivery

Formulation Duration Route Primary Indication(s)
Lupron 1 mg/day Daily SC injection SC CPP; ART protocols (pituitary down-regulation)
Lupron Depot 3.75 mg 1-month depot IM injection Endometriosis; uterine fibroids; prostate cancer
Lupron Depot 11.25 mg 3-month depot IM injection Endometriosis; prostate cancer; CPP
Lupron Depot 22.5 mg 3-month depot IM injection Prostate cancer
Lupron Depot 30 mg 4-month depot IM injection Prostate cancer
Eligard 45 mg 6-month depot (Atrigel polymer) SC injection Prostate cancer

Frequently Asked Questions

Q1: How does leuprolide suppress testosterone if it’s a GnRH agonist?

A1: This is the central pharmacological paradox of leuprolide and all GnRH agonist drugs. Leuprolide binds the pituitary GnRH receptor with 100-fold greater affinity than native GnRH and occupies it continuously via depot formulation. Continuous receptor occupancy drives a desensitization cascade: the receptor undergoes phosphorylation, beta-arrestin recruitment, and internalization into the cell. The net result is a profound reduction in surface GnRH receptor density and uncoupling from downstream signaling. After 2–4 weeks, the pituitary is essentially deaf to GnRH stimulation — LH and FSH secretion falls to near zero, and without LH drive the testes stop producing testosterone. The agonist produces suppression through receptor exhaustion, not through blocking.

Q2: What is the testosterone flare and why does it matter?

A2: Before pituitary desensitization is established, leuprolide’s initial agonism at GnRH receptors produces a stimulatory LH surge, which drives a transient testosterone rise — typically to 1.5–2x baseline — during the first 1–2 weeks of treatment. For most patients, this flare is clinically insignificant. For men with metastatic prostate cancer — particularly those with vertebral bone metastases, urinary obstruction, or high disease burden — the testosterone surge can trigger spinal cord compression, bone pain flare, or urinary retention. Standard of care for this population is concurrent antiandrogen therapy (bicalutamide) for the first 4 weeks to block androgen receptor activity during the flare period, before medical castration is established.

Q3: What are the side effects of leuprolide?

A3: Side effects are directly caused by the castrate sex hormone levels the drug is designed to produce — they are on-target pharmacological consequences, not off-target toxicities. In men: hot flashes (approximately 80%), loss of libido and erectile dysfunction (nearly universal), muscle mass and strength loss, increased fat mass, bone density loss, metabolic syndrome features, fatigue, anemia, cognitive effects, mood changes, and gynecomastia. In women: hot flashes (75–90%), vaginal dryness, decreased libido, mood changes, and bone density loss (clinically significant after 6 months — hence the 6-month maximum treatment duration without add-back therapy). Add-back therapy with low-dose norethindrone acetate and/or estrogen can substantially reduce hypoestrogenic side effects in women while preserving therapeutic benefit.

Q4: Is leuprolide used for endometriosis, and how does it work?

A4: Yes — leuprolide is FDA-approved for endometriosis. Ectopic endometrial tissue is estrogen-dependent: it proliferates under estrogen stimulation and regresses with estrogen deprivation. Leuprolide induces a temporary medical menopause — suppressing estrogen to castrate levels — causing ectopic implants to regress and pain to improve. The approved treatment duration is 6 months due to bone density loss with prolonged hypoestrogenism. Add-back therapy is commonly used to manage symptoms. The treatment is not curative: most women experience symptom recurrence after stopping as estrogen production resumes and residual implants re-activate. It is used for symptom control and preoperative lesion reduction, not as a permanent solution.

Q5: How is leuprolide used in gender-affirming care?

A5: Leuprolide is used off-label for puberty suppression in gender-dysphoric adolescents — the same GnRH agonist mechanism used for central precocious puberty, applied to halt the progression of endogenous puberty in a trans or nonbinary adolescent until decisions about gender-affirming hormone therapy are made. The pharmacology is identical to CPP use: HPG axis suppression preventing testosterone or estrogen-driven secondary sex characteristic development. The long-term CPP data confirms that pubertal suppression with GnRH agonists is reversible, and normal adult reproductive function can be achieved after stopping. For gender-affirming use, the subsequent path (continued suppression, cross-sex hormones, or stopping) is determined by the patient, family, and clinical team. This use is subject to legislative restrictions in some US states.

Q6: What is the evidence for leuprolide in prostate cancer?

A6: Leuprolide has one of the most extensive evidence bases in oncology — four decades of Phase III trials across multiple disease settings. ADT is standard-of-care across advanced, high-risk localized, and biochemically recurrent prostate cancer. Key milestones: leuprolide vs DES (1984, original approval data), CHAARTED (ADT + docetaxel in mHSPC), LATITUDE (ADT + abiraterone in high-risk mHSPC), ENZAMET and TITAN (ADT + next-generation antiandrogens). Median overall survival in metastatic hormone-sensitive prostate cancer has improved from approximately 3 years with ADT alone to 4–5+ years in favorable-risk patients on the best combination regimens. The efficacy of ADT is not in question; the clinical management challenge is the substantial quality-of-life impact of long-term testosterone deprivation.

Q7: How long does it take for testosterone to recover after stopping leuprolide?

A7: Testosterone recovery after stopping leuprolide begins within weeks after the last depot formulation wears off (the timeline depends on the depot duration — 1-month, 3-month, or 6-month). In most men, testosterone begins rising within 1–3 months after the depot effect expires. Full recovery to pre-treatment levels typically takes 6–18 months, with substantial individual variability. Recovery is slower after longer treatment duration, in older men, and in men with lower baseline testosterone. Approximately 10–20% of men do not recover to normal testosterone levels after long-term ADT — this is an irreversible hypogonadism that requires testosterone replacement therapy management. Men considering prostate cancer ADT who want to preserve fertility should discuss sperm banking before initiating treatment, as spermatogenesis recovery after ADT is not guaranteed.

Leuprolide is the most widely used GnRH agonist but is not the only one. Triptorelin and nafarelin share the same mechanism and are covered in their own articles in this cluster. Gonadorelin — the natural GnRH itself — is the mechanistic opposite when given pulsatilely and is the compound used to restore HPG axis function rather than suppress it. GnRH antagonists (cetrorelix, ganirelix, degarelix) block the GnRH receptor directly and achieve suppression without the initial testosterone flare — an important clinical distinction for prostate cancer and ART protocols. The table below covers all compounds in the Sexual Health & Hormonal cluster.

Summary and Key Takeaways

  • Leuprolide is a synthetic GnRH agonist that paradoxically suppresses sex hormone production through continuous GnRH receptor occupancy and pituitary desensitization. Same receptor as gonadorelin; opposite clinical effect.
  • FDA-approved indications: advanced prostate cancer (ADT), endometriosis, uterine fibroids (preoperative), and central precocious puberty. Off-label use: gender-affirming puberty suppression, ART protocols, other hormonal conditions.
  • Testosterone flare on initiation: 1–2 week testosterone surge before suppression — clinically significant in metastatic prostate cancer with bone/spinal metastases. Antiandrogen co-administration for 4 weeks is standard flare protection in that setting.
  • Prostate cancer evidence is among the most extensive in oncology — four decades of Phase III data establishing ADT as backbone therapy across metastatic, high-risk localized, and biochemically recurrent disease.
  • Side effects are on-target testosterone/estrogen deprivation consequences: hot flashes, sexual dysfunction, muscle loss, bone loss, metabolic syndrome, cardiovascular risk (men); hot flashes, vaginal dryness, bone loss (women). Add-back therapy mitigates hypoestrogenic effects in women.
  • Gender-affirming puberty suppression: same mechanism as CPP treatment; CPP long-term data confirm reversibility and normal adult outcomes; longer-duration gender-affirming use has a smaller but growing evidence base.
  • Multiple depot formulations (1-month to 6-month) provide flexible dosing intervals suited to patient and clinical context. Generic leuprolide available. WADA: not prohibited.
  • Cross-cluster compound: covered here for sexual/hormonal/reproductive applications; fully relevant to oncology with its own extensive evidence base in prostate cancer management.
Edit
Compound Type Primary Target Half-Life FDA Status WADA Status Evidence Tier Sexual Health Mechanism Receptor Target FDA Approved Indication Key Differentiator
PT-141 (Bremelanotide) Synthetic heptapeptide (Ac-Nle-cyclo(Asp-His-D-Nal(2′)-Arg-Trp-Lys)-NH2, melanocortin agonist) MC1R / MC4R (melanocortin-4 receptor in hypothalamus) ~2–4 hours FDA-approved (Vyleesi, 2019 for female hypoactive sexual desire disorder — HSDD) Prohibited — S4 (Hormone analog / Melanocortin peptide agonist) Tier 1 — Approved Drug Central melanocortin pathway activation (hypothalamic appetite/sexual behavior integration); genital arousal signaling MC1R (skin pigmentation); MC4R (sexual desire, appetite centers in hypothalamus) Female HSDD (hypoactive sexual desire disorder) — FDA approved 2019. Subcutaneous injection (pre-coitus dosing) Only FDA-approved peptide for sexual dysfunction. Off-label use in males reported but not approved. Requires frequent pre-coitus dosing
Melanotan II (MT-II) Synthetic non-peptide cyclic melanocortin agonist (Ac-Nle-cyclo(Asp-His-D-Phe(4-I)-Arg-Trp-Lys)-NH2, similar to PT-141 but with iodinated D-Phe) MC1R / MC4R (melanocortin-4 receptor, broader activation than PT-141) ~4–6 hours Not FDA-approved (research/investigational compound) Prohibited — S4 (Hormone analog / Melanocortin peptide agonist) Tier 3 — Pilot / Limited Human Data Melanocortin pathway agonism; sexual arousal (reported in males and females); pigmentation/tanning (off-target effect) MC1R (skin) >> MC4R (hypothalamic sexual/appetite centers) — broad melanocortin activation No FDA indication (investigational). Off-label interest for erectile dysfunction and female sexual arousal Broader melanocortin agonism than PT-141. Significant tanning/pigmentation as off-target effect. Injectable only (research compound)
Leuprolide (Lupron) Synthetic decapeptide GnRH agonist (Ac-D-Leu(1)-Pro(2)-ethylamide-D-Trp(6)-LH-RH, synthetic LHRH analog) GnRH-R (gonadotropin-releasing hormone receptor; agonist-mediated desensitization at higher doses) ~3–4 hours (injection); ~1 month (depot formulations) FDA-approved (multiple indications: prostate cancer, endometriosis, precocious puberty, breast cancer palliative care) Prohibited — S2 (GnRH analog, hormone) Tier 1 — Approved Drug GnRH agonism → Initial LH/FSH surge → Downregulation → Testosterone suppression (chemical castration for cancer/endo); precocious puberty halting GnRH-R (pituitary gonadotroph cells); biphasic agonist-antagonist (flare then suppression) Prostate cancer (palliative), endometriosis, precocious puberty, uterine fibroids, breast cancer palliative FDA-approved since 1989. Extended-release formulations (1-, 3-, 6-, 12-month depot). No sexual enhancement indication; used for hormone suppression

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

Selected References and Key Studies

  1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–7. — Nobel Prize-recognized foundational androgen deprivation rationale
  2. Swerdlow AJ, et al. Leuprolide in the treatment of patients with cancer. N Engl J Med. 1984;311(19):1281. — original Phase III ADT approval data
  3. Sweeney CJ, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer (CHAARTED). N Engl J Med. 2015;373(8):737–46. PMID 26244877
  4. Fizazi K, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer (LATITUDE). N Engl J Med. 2017;377(4):352–60. PMID 28578607
  5. Carel JC, et al. Long-term treatment with the GnRH agonist triptorelin for central precocious puberty: predictive factors of adult height. J Clin Endocrinol Metab. 2006;91(5):1662–9. PMID 16537683
  6. Hughes IA. Consequences of fetal programming by endocrine disruption. Best Pract Res Clin Endocrinol Metab. 2006;20(1):1–13. — reproductive outcomes context
  7. Hembree WC, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102(11):3869–903. PMID 28945902

Further Reading

Disclaimer

This article is produced for educational and research purposes only. Peptidings does not provide medical advice, diagnosis, or treatment recommendations. Nothing here should be interpreted as a recommendation to use leuprolide for any purpose.

Leuprolide is an FDA-approved prescription medication. Its use requires physician evaluation, appropriate indication, and ongoing monitoring. ADT for prostate cancer should be managed by a urologist or medical oncologist. Endometriosis and fibroid treatment requires gynecological evaluation. CPP management requires a pediatric endocrinologist. Gender-affirming puberty suppression requires specialist evaluation per WPATH and Endocrine Society guidelines.

Consult a qualified physician for any questions about leuprolide use.

Scroll to Top